ATR Leads Coalition Opposing Price Controls on Medical Innovation

Share on Facebook
Tweet this Story
Pin this Image

Posted on Wednesday, November 17th, 2021, 4:00 AM PERMALINK

Today, Americans for Tax Reform led a coalition letter in opposition to Democrats' plan to impose price controls, a 95 percent excise tax, and inflation penalties on American pharmaceutical manufacturers. Democrats are attempting to include this plan in their socialist tax-and-spend bill. The letter was signed by 51 organizations. 

This proposal would impose price controls on up to 20 medicines in Medicare Part B and Part D. If the manufacturer does not accept this government-set price, they are hit with a 95 percent excise tax on the total revenues of the drug. While it is imposed on a small group of medicines, it creates a new tax and regulatory structure that can be expanded to all cures and to the entire healthcare system, becoming a stepping stone toward socialized healthcare. 

The proposal also includes an inflationary rebate penalty on every medicine, an arbitrary policy that could create an incentive for manufacturers to automatically increase the list price of their drugs each year to keep pace with inflation. 

While supporters of government price controls on American medicine argue they would allow the government to negotiate with the private sector, these policies would harm competition and access to cures, crush medical innovation, upend the market-based structure of Medicare Part D, and cost high-paying American jobs.

The letter urges members of Congress to oppose this dangerous plan.

The full letter can be found here.

Photo Credit: "Male biomedical engineer conducts medical experiment" by This is Engineering is licensed under CC BY-NC-ND 2.0.

×